Pharma Mar (OTCMKTS:PHMMF) Stock Rating Upgraded by Zacks Research

Pharma Mar (OTCMKTS:PHMMF) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

PHMMF has been the topic of a number of other research reports. BTIG Research began coverage on shares of Pharma Mar in a report on Thursday, April 23rd. They issued a “buy” rating on the stock. Chardan Capital raised Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Pharma Mar currently has an average rating of “Buy”.

Pharma Mar Price Performance

OTCMKTS PHMMF opened at $79.49 on Monday. Pharma Mar has a one year low of $77.41 and a one year high of $110.40. The company has a 50-day simple moving average of $104.27 and a 200-day simple moving average of $94.45. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.